Un año más, ESTEVE ha obtenido la calificación de ‘excelente’ por sus actividades scientific research, technological development and innovation grants Profarma Plan, the Ministry of Industry. It is a distinction the company has achieved continuously for 25 years, when it launched the Plan in 1986.
innovation and internationalization are two strategic axes ESTEVE, a company that invests around 60 million euros annually in research and has a team of nearly 2,900 professionals, of which 11% is devoted specifically to R & D. The result of this strong commitment and effort, is the annual renewal of the top rating in Profarma, an official stamp of quality promotes the R & D in the pharmaceutical sector.
Specifically, ESTEVE is drawn in Group A Profarma Plan, which includes those pharmaceutical companies with significant research activity actually plant or R & D center itself (basic or preclinical).
0 comments:
Post a Comment